A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM

PHASE3CompletedINTERVENTIONAL

Enrollment

214

Participants

Timeline

Start Date

January 14, 2020

Primary Completion Date

June 3, 2021

Study Completion Date

June 3, 2021

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

DBPR108

DBPR108: 100 mg, once daily for 24 weeks.

DRUG

metformin hydrochloride

metformin hydrochloride: 500 mg, 1-3 times daily for 24 weeks.

DRUG

placepo

placebo:100 mg, once daily for 24 weeks.

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT04218734 - A Study of DBPR108 and Metformin Hydrochloride Combination Therapy in Patients With T2DM | Biotech Hunter | Biotech Hunter